RYBREVANT (Amivantamab) Plus LAZCLUZE (Lazertinib) Demonstrates Durable Clinical Benefit as First-Line Therapy in Advanced NSCLC with Atypical EGFR Mutations

May 29, 2026Johnson & JohnsonJohnson & Johnson (JNJ) announced updated results from the Phase 1/1b CHRYSALIS-2 study, evaluating the efficacy of RYBREVANT in combination with LAZCLUZE for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGFR mutations.

Patients with non-small cell lung cancer (NSCLC) harboring atypical EGFR mutations have a poor prognosis and limited effective first-line treatment options; these mutations account for approximately 10–20% of all EGFR-mutated cases.

Cohort C of the study evaluated this combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring atypical EGFR mutations (excluding EGFR exon 20 insertion mutations) (n = 49). Common mutations included G719X (55%), S768X (27%), and L861X (24%), with 35% of patients carrying multiple atypical mutations. The previously reported objective response rate was 57%. At a median follow-up of 31.3 months, the median overall survival was nearly 3.5 years (41.0 months; 95% CI, 27.7 to not estimable), with 3-year and 4-year overall survival rates of 55% and 46%, respectively.

The safety profile was consistent with previous reports, with no new safety signals observed. Most adverse events were Grade 1 or 2. Common treatment-related adverse events included paronychia (78%) and rash (65%).

RYBREVANT has been approved for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. These results clearly demonstrate the long-term efficacy of this combination therapy as a first-line treatment for patients with atypical EGFR mutations. Data presented at the 2026 ASCO Annual Meeting highlight its potential application across various tumor types.

Future attention should be paid to the performance of RYBREVANT in combination with LAZCLUZE in more clinical studies, as well as its application progress in different tumor types. At the same time, close monitoring is required for treatment-related adverse reactions, such as hypersensitivity reactions, infusion-related reactions, and interstitial lung disease/pneumonitis.

Responsible Editor: Xiaolang Express